Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 5/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | HTR2A | P28223 | 4/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimethixene SCHEMBL301596 | 1.00 | SETD7 (1.00) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| Pimethixene SCHEMBL301226 | 0.87 | HTT (1.00) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| SCHEMBL11573964 | 0.87 | KCNH2 (0.76) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| Pimethixene SCHEMBL301225 | 0.87 | HTT (1.00) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| SCHEMBL11575971 | 0.87 | SETD7 (0.76) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| SCHEMBL11573081 | 0.87 | SETD7 (0.76) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| SCHEMBL11432245 | 0.87 | HTR1A (0.76) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| SCHEMBL11574284 | 0.87 | SETD7 (0.76) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| SCHEMBL11600806 | 0.85 | DRD3 (0.73) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| SCHEMBL11431794 | 0.85 | SETD7 (0.72) | SETD7CHRM2CHRM1ADRA1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| CN-119082349-A | Primer pair, kit and method for identifying Stemona sessilifolia traditional Chinese medicine raw plants, medicinal materials or decoction pieces with different origins | 广东一方制药有限公司 | 2024-12-06 | — | — | CN | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| CN-114457143-B | Method for constructing CNV detection library and CNV detection method | 苏州贝康医疗器械有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-115651974-B | Artificial simulated cfDNA standard, preparation method and application thereof | 纳昂达(南京)生物科技有限公司 | 2024-03-08 | — | — | CN | claimed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | claimed |
| CN-115651974-A | Artificial simulation cfDNA standard substance and preparation method and application thereof | 纳昂达(南京)生物科技有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-113281117-B | Preparation method of synthetic surface | 中国空间技术研究院 | 2022-12-06 | — | — | CN | claimed |
| CN-114457143-A | Method for constructing CNV detection library and CNV detection method | 苏州贝康医疗器械有限公司 | 2022-05-10 | — | — | CN | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | disclosed |
| US-12624113-B2 | Anti-human CCR1 monoclonal antibody | KYOWA KIRIN CO., LTD. (JP) | 2026-05-12 | — | — | US | disclosed |
| US-12606615-B2 | Anti-FGF23 antibody or antibody fragment thereof | KYOWA KIRIN CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12601006-B2 | Targeted, long-read nucleic acid sequencing for the determination of cytosine modifications | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (CH) | 2026-04-14 | — | — | US | disclosed |
| US-20260092110-A1 | ANTIBODY WHICH BINDS TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN | KYOWA KIRIN CO., LTD. (JP) | 2026-04-02 | — | — | US | disclosed |
| CN-114005490-B | Circulating tumor DNA fusion detection method based on second-generation sequencing technology | 北京优迅医疗器械有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114277120-A | Medicine for treating alpha-thalassemia and diagnostic kit | 深圳市坪山区人民医院 | 2022-04-05 | — | — | CN | disclosed |
| EP-3971293-A1 | BISPECIFIC ANTIBODY CAPABLE OF BINDING TO CD40 AND GPC3 | Kyowa Kirin Co., Ltd. (JP) | 2022-03-23 | — | — | EP | disclosed |
| EP-3970743-A1 | BISPECIFIC ANTIBODY BINDING TO CD40 AND FAP | Kyowa Kirin Co., Ltd. (JP) | 2022-03-23 | — | — | EP | disclosed |
| CN-114005490-A | Circulating tumor DNA fusion detection method based on second-generation sequencing technology | 北京优迅医疗器械有限公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12601006-B2 | Targeted, long-read nucleic acid sequencing for the determination of cytosine modifications | TET1, TET3, TET2 | SETD7 683/4885CHRM2 4789/4885CHRM1 4706/4885 |
| US-12606615-B2 | Anti-FGF23 antibody or antibody fragment thereof | FGF23, IGLV6-57, FCGR3B | SETD7 869/4885CHRM2 2658/4885CHRM1 3100/4885 |
| US-12624113-B2 | Anti-human CCR1 monoclonal antibody | CCR1, CCR4, CCRL2 | SETD7 433/4885CHRM2 1451/4885CHRM1 1648/4885 |
| US-20260092110-A1 | ANTIBODY WHICH BINDS TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN | MAG, IGSF11, GMFG | SETD7 1584/4885CHRM2 1504/4885CHRM1 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.